171 related articles for article (PubMed ID: 24224638)
1. Pazopanib versus sunitinib in renal cancer.
Casper J; Schumann-Binarsch S; Köhne CH
N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224638
[No Abstract] [Full Text] [Related]
2. Pazopanib versus sunitinib in renal cancer.
Wittes J
N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224637
[No Abstract] [Full Text] [Related]
3. Pazopanib versus sunitinib in renal cancer.
Ramaekers R; Tharnish M; Copur MS
N Engl J Med; 2013 Nov; 369(20):1968-9. PubMed ID: 24224636
[No Abstract] [Full Text] [Related]
4. Pazopanib versus sunitinib in renal cancer.
Motzer RJ; McCann L; Deen K
N Engl J Med; 2013 Nov; 369(20):1970. PubMed ID: 24224635
[No Abstract] [Full Text] [Related]
5. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Sun M; Trinh QD; Perrotte P; Karakiewicz PI
Eur Urol; 2014 May; 65(5):1014-5. PubMed ID: 24646500
[No Abstract] [Full Text] [Related]
6. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Ouzaid I; Rini B
Eur Urol; 2014 Mar; 65(3):667-8. PubMed ID: 24484761
[No Abstract] [Full Text] [Related]
7. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK
N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224
[No Abstract] [Full Text] [Related]
8. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract][Full Text] [Related]
11. Kidney cancer: Comparing first-line treatments for mRCC.
Phillips R
Nat Rev Urol; 2013 Oct; 10(10):557. PubMed ID: 24018564
[No Abstract] [Full Text] [Related]
12. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
13. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
15. Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma.
Diaz J; Sternberg CN; Mehmud F; Delea TE; Latimer N; Pandite L; Motzer RJ
Oncology; 2016; 90(3):119-26. PubMed ID: 26901053
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
18. First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile.
Iacovelli R; Verzoni E; De Braud F; Procopio G
Cancer Biol Ther; 2014 Jan; 15(1):19-21. PubMed ID: 24253418
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
20. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]